Compagnie Lombard Odier SCmA’s Aimmune Therapeutics AIMT Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$34K	–	626
2020 Q3	$34K	Hold	1,000	–	–	﹤0.01%	422
2020 Q2	$17K	Hold	1,000	–	–	﹤0.01%	454
2020 Q1	$14K	Hold	1,000	–	–	﹤0.01%	425
2019 Q4	$33K	Buy	+1,000	New	+$28K	﹤0.01%	389

Compagnie Lombard Odier SCmA's AIMT Position: Q4 2020 in Review

Compagnie Lombard Odier SCmA sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,000 shares — an estimated $34K sold.

Compagnie Lombard Odier SCmA first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $34K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Compagnie Lombard Odier SCmA reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 1,000 Aimmune Therapeutics shares in Q4 2020, an estimated $34K.
Compagnie Lombard Odier SCmA first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
Compagnie Lombard Odier SCmA's Aimmune Therapeutics position peaked at $34K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2020, filed 9 Feb 2021.